The FDA has accepted Sanofi and Regeneron’s application to expand Dupixent’s use, with a decision expected by April 2025.

EPA proposed to require a label on existing plastic shipping pallets that contain decaBDE to provide notice that personal protective equipment (PPE) is required during the recycling of the pallets.